{"id":258195,"date":"2026-10-09T17:41:55","date_gmt":"2026-10-09T15:41:55","guid":{"rendered":"https:\/\/r3i.org\/?page_id=258195"},"modified":"2026-10-09T17:42:00","modified_gmt":"2026-10-09T15:42:00","slug":"landmark-october-2026","status":"publish","type":"page","link":"https:\/\/r3i.org\/ja\/landmark-october-2026\/","title":{"rendered":"Landmark – October 2026"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”1px|||||” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” header_2_text_color=”gcid-primary-color” header_5_text_color=”gcid-secondary-color” text_orientation=”center” width=”99%” custom_margin=”|-147px||||” custom_padding=”|0px||||” hover_enabled=”0″ global_colors_info=”{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22,%22quote_text_color%22,%22header_2_text_color%22%93,%22gcid-secondary-color%22:%91%22header_5_text_color%22%93}” sticky_enabled=”0″]<\/p>\n

HPS-4\/TIMI 65\/ORION-4\uff1a\u30a4\u30f3\u30af\u30ea\u30b7\u30e9\u30f3\u306e\u5fc3\u8840\u7ba1\u30a2\u30a6\u30c8\u30ab\u30e0\u8a66\u9a13<\/h2>\n

2026\u5e7410\u6708<\/span><\/h5>\n
\n
\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n

\u30a2\u30c6\u30ed\u30fc\u30e0\u6027\u52d5\u8108\u786c\u5316\u6027\u5fc3\u8840\u7ba1\u75be\u60a3\u304c\u78ba\u7acb\u3057\u305f16,000\u4f8b\u8d85\u3092\u5bfe\u8c61\u3068\u3059\u308b\u30a4\u30f3\u30af\u30ea\u30b7\u30e9\u30f3\u306eORION-4\u8a66\u9a13\u304b\u3089\u3001\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u30c7\u30fc\u30bf\u304c\u5831\u544a\u3055\u308c\u305f\u3002\u7d50\u679c\u306f2027\u5e74\u521d\u982d\u306b\u516c\u8868\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3042\u308b\u3002 <\/em><\/p>\n

Mafham M, Zayed M, Collins R, et al<\/em>. HPS-4\/TIMI 65\/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J 2026; https:\/\/doi.org\/10.1016\/j.ahj.2026.107546<\/a> <\/em><\/p>\n

\u7814\u7a76\u6982\u8981<\/strong><\/p>\n\n\n\n\n\n\n\n\n
\n

\u76ee\u7684<\/strong><\/p>\n<\/td>\n

\n

ORION-4\u8a66\u9a13\u306f\u3001\u30a2\u30c6\u30ed\u30fc\u30e0\u6027\u52d5\u8108\u786c\u5316\u6027\u5fc3\u8840\u7ba1\u75be\u60a3\uff08ASCVD\uff09\u306e\u65e2\u5f80\u304c\u3042\u308b\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u3001\u4f4e\u5206\u5b50\u5e72\u6e09RNA\uff08siRNA\uff09\u88fd\u5264\u3067\u3042\u308b\u30a4\u30f3\u30af\u30ea\u30b7\u30e9\u30f3\u306e\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u6291\u5236\u52b9\u679c\u3068\u5b89\u5168\u6027\u3092\u8a55\u4fa1\u3057\u3066\u3044\u308b<\/p>\n

 <\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

\u7814\u7a76\u30c7\u30b6\u30a4\u30f3<\/strong><\/p>\n<\/td>\n

\n

\u82f1\u56fd\u3068\u7c73\u56fd\u3067\u884c\u308f\u308c\u3066\u3044\u308b\u4e8c\u91cd\u76f2\u691c\u3001\u7121\u4f5c\u70ba\u5316\u3001\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u306e\u5fc3\u8840\u7ba1\u30a2\u30a6\u30c8\u30ab\u30e0\u8a66\u9a13\u3002\u60a3\u8005\u306f\u30a4\u30f3\u30af\u30ea\u30b7\u30e9\u30f3300 mg\u7fa4\u3068\u5bfe\u5fdc\u3059\u308b\u30d7\u30e9\u30bb\u30dc\u7fa4\u306b1:1\u3067\u5272\u308a\u4ed8\u3051\u3089\u308c\u305f\uff08\u7121\u4f5c\u70ba\u5316\u5f53\u65e5\u30013\u304b\u6708\u5f8c\u3001\u4ee5\u964d6\u304b\u6708\u3054\u3068\u306b\u76ae\u4e0b\u6ce8\u5c04\uff09\u3002\u7121\u4f5c\u70ba\u5316\u304b\u3089\u306e\u8ffd\u8de1\u671f\u9593\u306f\u4e2d\u592e\u50245\u5e74\u4ee5\u4e0a\u3092\u4e88\u5b9a\u3057\u3066\u3044\u308b\u3002
<\/span><\/p>\n

 <\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

\u7814\u7a76\u5bfe\u8c61\u8005<\/strong><\/p>\n<\/td>\n

\n

ASCVD\u304c\u78ba\u7acb\u3057\u305f\u60a3\u800515,000\u4f8b\u4ee5\u4e0a\u306e\u767b\u9332\u3092\u76ee\u6a19\u3068\u3057\u305f\u3002\u4e3b\u8981\u6709\u52b9\u6027\u30a2\u30a6\u30c8\u30ab\u30e0\u306e\u767a\u751f\u30ea\u30b9\u30af\u304c\u5341\u5206\u306b\u9ad8\u304440\u6b73\u4ee5\u4e0a\u306e\u7537\u6027\uff08\u5f53\u521d\u306f55\u6b73\u4ee5\u4e0a\uff09\u306855\u6b73\u4ee5\u4e0a\u306e\u5973\u6027\u304c\u9069\u683c\u3068\u3055\u308c\u305f\u3002\u5f53\u521d\u306f\u7dcf\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb155 mg\/dL\uff084.0 mmol\/L\uff09\u4ee5\u4e0a\u3092\u9069\u683c\u6027\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u306e\u57fa\u6e96\u3068\u3057\u3066\u3044\u305f\u304c\u3001\u904b\u55b6\u59d4\u54e1\u4f1a\u306e\u52e7\u544a\u306b\u3088\u308a\u30012021\u5e747\u6708\u306b135 mg\/dL\uff083.5 mmol\/L\uff09\u4ee5\u4e0a\u30012022\u5e746\u6708\u306b116 mg\/dL\uff083.0 mmol\/L\uff09\u4ee5\u4e0a\u3078\u3068\u5f15\u304d\u4e0b\u3052\u3089\u308c\u305f\u3002 <\/p>\n

 <\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee<\/strong><\/p>\n<\/td>\n

\n

\u4e3b\u8981\u6709\u52b9\u6027\u30a2\u30a6\u30c8\u30ab\u30e0\u306f\u4e3b\u8981\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\uff08MACE\uff09\u3067\u3001\u51a0\u52d5\u8108\u75be\u60a3\uff08CHD\uff09\u6b7b\u3001\u5fc3\u7b4b\u6897\u585e\u3001\u81f4\u6b7b\u7684\u307e\u305f\u306f\u975e\u81f4\u6b7b\u7684\u865a\u8840\u6027\u8133\u5352\u4e2d\u3001\u7dca\u6025\u51a0\u8840\u884c\u518d\u5efa\u8853\u306e\u8907\u5408\u3068\u5b9a\u7fa9\u3055\u308c\u305f\u3002\u526f\u6b21\u6709\u52b9\u6027\u30a2\u30a6\u30c8\u30ab\u30e0\u306f\u3001(i) \u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u3067\u9ad8\u5f37\u5ea6\u30b9\u30bf\u30c1\u30f3\u3092\u670d\u7528\u3057\u3066\u3044\u305f\u60a3\u8005\u3067\u306eMACE\u3001(ii) CHD\u6b7b\u307e\u305f\u306f\u5fc3\u7b4b\u6897\u585e\u306e\u8907\u5408\u3001(iii) \u5fc3\u8840\u7ba1\u6b7b\u3067\u3042\u308b\u3002 <\/p>\n

 <\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

\u65b9\u6cd5<\/strong><\/p>\n<\/td>\n

\n

ORION-4\u8a66\u9a13\u306f\u3001\u30aa\u30c3\u30af\u30b9\u30d5\u30a9\u30fc\u30c9\u5927\u5b66\u306eClinical Trial Service Unit\uff08CTSU\uff09\u304c\u4e3b\u5c0e\u3057\u3001\u30dc\u30b9\u30c8\u30f3\u306e\u30cf\u30fc\u30d0\u30fc\u30c9\u5927\u5b66\u533b\u5b66\u90e8Brigham and Women\u2019s Hospital\u306eTIMI Study Group\u3068\u5171\u540c\u3067\u5b9f\u65bd\u3057\u3066\u3044\u308b\u3002<\/p>\n

 <\/p>\n

\u9069\u683c\u3068\u898b\u8fbc\u307e\u308c\u308b\u60a3\u8005\u306f\u307e\u305a\u5358\u76f2\u691c\u306e\u7121\u4f5c\u70ba\u5316\u524d\u5c0e\u5165\u671f\u306b\u5165\u308a\u3001\u30d7\u30e9\u30bb\u30dc\u306e\u76ae\u4e0b\u6ce8\u5c04\u3092\u53d7\u3051\u305f\u3002\u3053\u306e\u5c0e\u5165\u671f\u306f\u3001\u9577\u671f\u306e\u8a66\u9a13\u6cbb\u7642\u3084\u8ffd\u8de1\u3092\u7d9a\u3051\u3089\u308c\u305d\u3046\u306b\u306a\u3044\u60a3\u8005\u3092\u7121\u4f5c\u70ba\u5316\u524d\u306b\u898b\u6975\u3081\u3066\u9664\u5916\u3059\u308b\u305f\u3081\u306b\u8a2d\u3051\u3089\u308c\u305f\u3002\u9069\u683c\u60a3\u8005\u306f\u7121\u4f5c\u70ba\u5316\u3055\u308c\u30018\u9031\u9593\u5f8c\u306e\u6765\u9662\u6642\u306b\u521d\u56de\u306e\u8a66\u9a13\u6cbb\u7642\u3092\u53d7\u3051\u305f\u3002\u305d\u306e\u5f8c\u306f3\u304b\u6708\u5f8c\u306b\u3001\u4ee5\u964d\u306f\u8a66\u9a13\u7d42\u4e86\u307e\u30676\u304b\u6708\u3054\u3068\u306b\u6765\u9662\u3059\u308b\u3002\u7121\u4f5c\u70ba\u5316\u6642\u3068\u4e00\u90e8\u306e\u8ffd\u8de1\u6765\u9662\u6642\u306b\u975e\u7a7a\u8179\u6642\u63a1\u8840\u3092\u884c\u3044\u3001\u4e2d\u592e\u691c\u67fb\u5ba4\u3067\u6e2c\u5b9a\u3057\u305f\u3002\u8a66\u9a13\u85ac\u4ee5\u5916\u306e\u8102\u8cea\u4f4e\u4e0b\u7642\u6cd5\uff08\u30b9\u30bf\u30c1\u30f3\u3092\u542b\u3080\uff09\u306f\u3001\u8a66\u9a13\u671f\u9593\u3092\u901a\u3058\u3066\u5404\u60a3\u8005\u306e\u4e3b\u6cbb\u533b\u306b\u4efb\u3055\u308c\u305f\u3002 <\/p>\n

 <\/p>\n

\u72ec\u7acb\u30c7\u30fc\u30bf\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u59d4\u54e1\u4f1a\u304c\u3001\u3059\u3079\u3066\u306e\u91cd\u7be4\u306a\u6709\u5bb3\u4e8b\u8c61\u3068\u305d\u306e\u4ed6\u306e\u30a2\u30a6\u30c8\u30ab\u30e0\u306b\u3064\u3044\u3066\u975e\u76f2\u691c\u306e\u4e2d\u9593\u89e3\u6790\u3092\u5be9\u67fb\u3057\u305f\u3002\u6709\u52b9\u6027\u306e\u4e2d\u9593\u89e3\u6790\u306f2025\u5e74\u306b1\u56de\u884c\u308f\u308c\u3066\u3044\u308b\u3002\u4e3b\u8981\u8a55\u4fa1\u306f\u3001\u7121\u4f5c\u70ba\u5316\u304b\u3089\u306e\u8ffd\u8de1\u671f\u9593\u304c\u4e2d\u592e\u50245\u5e74\u4ee5\u4e0a\u306b\u9054\u3057\u3001\u304b\u3064\u5224\u5b9a\u6e08\u307fMACE\u304c1,700\u4f8b\u4ee5\u4e0a\u767a\u751f\u3057\u305f\u6642\u70b9\u3067\u3001MACE\u306b\u5bfe\u3059\u308b\u30a4\u30f3\u30af\u30ea\u30b7\u30e9\u30f3\u306e\u52b9\u679c\u3092intention-to-treat\u3067\u6bd4\u8f03\u3059\u308b\u3082\u306e\u3067\u3042\u308b\u3002 <\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

\u4e3b\u306a\u7d50\u679c<\/strong><\/p>\n<\/td>\n

\n

\u9069\u683c\u6027\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u3092\u53d7\u3051\u305f33,461\u4f8b\u306e\u3046\u306118,569\u4f8b\u304c\u30d7\u30e9\u30bb\u30dc\u306b\u3088\u308b\u5358\u76f2\u691c\u5c0e\u5165\u671f\u306b\u5165\u308a\u3001\u6700\u7d42\u7684\u306b16,124\u4f8b\u304c\u7121\u4f5c\u70ba\u5316\u3055\u308c\u305f\u3002\u82f1\u56fd109\u65bd\u8a2d\u306713,190\u4f8b\uff0882%\uff09\u3001\u7c73\u56fd84\u65bd\u8a2d\u30672,934\u4f8b\uff0818%\uff09\u304c\u767b\u9332\u3055\u308c\u305f\u3002\u60a3\u8005\u80cc\u666f\u3092\u88681\u306b\u793a\u3059\u3002 <\/p>\n

 <\/p>\n

\u88681\u3000ORION-4\u8a66\u9a13\u306e\u60a3\u8005\u80cc\u666f <\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

 <\/p>\n<\/td>\n

\n

UK<\/p>\n

(N=13190)<\/p>\n<\/td>\n

\n

USA<\/p>\n

(N=2934)<\/p>\n<\/td>\n

\n

\u5408\u8a08<\/p>\n

(N=16124)<\/p>\n<\/td>\n<\/tr>\n

\n

No. (%) male<\/p>\n<\/td>\n

\n

9565 (73)<\/p>\n<\/td>\n

\n

1694 (58)<\/p>\n<\/td>\n

\n

11259 (70)<\/p>\n<\/td>\n<\/tr>\n

\n

Mean (SD) age, years<\/p>\n<\/td>\n

\n

70.4 (8.0)<\/p>\n<\/td>\n

\n

68.2 (8.2)<\/p>\n<\/td>\n

\n

70.0 (8.1)<\/p>\n<\/td>\n<\/tr>\n

\n

<65 years, %<\/p>\n<\/td>\n

\n

26%<\/p>\n<\/td>\n

\n

34%<\/p>\n<\/td>\n

\n

28%<\/p>\n<\/td>\n<\/tr>\n

\n

Statin, no. (%)<\/p>\n<\/td>\n

\n

11474 (87)<\/p>\n<\/td>\n

\n

2261 (77)<\/p>\n<\/td>\n

\n

13735 (85)<\/p>\n<\/td>\n<\/tr>\n

\n

Intensive<\/p>\n<\/td>\n

\n

6893 (52)<\/p>\n<\/td>\n

\n

1596 (54)<\/p>\n<\/td>\n

\n

8489 (53)<\/p>\n<\/td>\n<\/tr>\n

\n

Moderate\/low<\/p>\n<\/td>\n

\n

4581 (35)<\/p>\n<\/td>\n

\n

665 (23)<\/p>\n<\/td>\n

\n

5246 (33)<\/p>\n<\/td>\n<\/tr>\n

\n

None<\/p>\n<\/td>\n

\n

1716 (13)<\/p>\n<\/td>\n

\n

673 (23)<\/p>\n<\/td>\n

\n

2389 (15)<\/p>\n<\/td>\n<\/tr>\n

\n

ASCVD, no. (%)<\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

\u6162\u6027\u9589\u585e\u6027\u80ba\u75be\u60a3<\/p>\n<\/td>\n

\n

10134 (77)<\/p>\n<\/td>\n

\n

2414 (82)<\/p>\n<\/td>\n

\n

12548 (78)<\/p>\n<\/td>\n<\/tr>\n

\n

\u865a\u8840\u6027\u8133\u5352\u4e2d<\/p>\n<\/td>\n

\n

2795 (21)<\/p>\n<\/td>\n

\n

722 (25)<\/p>\n<\/td>\n

\n

3517 (22)<\/p>\n<\/td>\n<\/tr>\n

\n

\u30d1\u30c3\u30c9<\/p>\n<\/td>\n

\n

1948 (15)<\/p>\n<\/td>\n

\n

513 (17)<\/p>\n<\/td>\n

\n

2461 (15)<\/p>\n<\/td>\n<\/tr>\n

\n

Diabetes, no. (%)<\/p>\n<\/td>\n

\n

2650 (20)<\/p>\n<\/td>\n

\n

1092 (37)<\/p>\n<\/td>\n

\n

3742 (23)<\/p>\n<\/td>\n<\/tr>\n

\n

Lipids, Mean (SD), mg\/dL<\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

Total cholesterol<\/p>\n<\/td>\n

\n

184 (38)<\/p>\n<\/td>\n

\n

199 (50)<\/p>\n<\/td>\n

\n

186 (41)<\/p>\n<\/td>\n<\/tr>\n

\n

LDL cholesterol<\/p>\n<\/td>\n

\n

94 (30)<\/p>\n<\/td>\n

\n

105 (38)<\/p>\n<\/td>\n

\n

96 (32)<\/p>\n<\/td>\n<\/tr>\n

\n

CHD\uff1a\u51a0\u52d5\u8108\u75be\u60a3\u3001PAD\uff1a\u672b\u68a2\u52d5\u8108\u75be\u60a3\u3001SD\uff1a\u6a19\u6e96\u504f\u5dee<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

\u8a66\u9a13\u96c6\u56e3\u5168\u4f53\u3092\u307f\u308b\u3068\u3001\u7537\u6027\u304c\u591a\u304f\uff0870%\uff09\u3001\u9ad8\u9f62\u3067\uff08\u5e73\u574770\u6b73\u3001\u7d043\u5206\u306e2\u304c65\u6b73\u4ee5\u4e0a\uff09\u3001\u5927\u534a\u304cCHD\u306e\u65e2\u5f80\u3092\u3082\u3063\u3066\u3044\u305f\uff0878%\uff09\u3002\u307b\u3068\u3093\u3069\u306e\u60a3\u8005\u304c\u30b9\u30bf\u30c1\u30f3\u6cbb\u7642\u3092\u53d7\u3051\u3066\u304a\u308a\u3001\u305d\u306e\u7d04\u534a\u6570\uff0853%\uff09\u306f\u9ad8\u5f37\u5ea6\u30ec\u30b8\u30e1\u30f3\u3067\u3042\u3063\u305f\u3002\u305d\u306e\u4ed6\u306e\u8102\u8cea\u4f4e\u4e0b\u7642\u6cd5\u3092\u53d7\u3051\u3066\u3044\u308b\u60a3\u8005\u306f\u5c11\u306a\u304b\u3063\u305f\uff08\u30a8\u30bc\u30c1\u30df\u30d68%\u3001\u30d5\u30a3\u30d6\u30e9\u30fc\u30c82%\u3001\u30d9\u30e0\u30da\u30c9\u9178\u307e\u305f\u306f\u30a4\u30b3\u30b5\u30da\u30f3\u30c8\u9178\u30a8\u30c1\u30eb1%\u672a\u6e80\uff09\u3002\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u306e\u5e73\u5747LDL-C\u306f96 mg\/dL\uff082.49 mmol\/L\uff09\u3067\u3001\u9ad8\u5f37\u5ea6\u30b9\u30bf\u30c1\u30f3\u7fa4\u3068\u4e2d\uff0f\u4f4e\u5f37\u5ea6\u30b9\u30bf\u30c1\u30f3\u7fa4\u306e\u9593\u306b\u5927\u304d\u306a\u5dee\u306f\u306a\u304b\u3063\u305f\uff08\u305d\u308c\u305e\u308c87 mg\/dL\uff3b2.25 mmol\/L\uff3d\u300193 mg\/dL\uff3b2.41 mmol\/L\uff3d\uff09\u3002 <\/p>\n<\/td>\n<\/tr>\n

\n

\u8457\u8005\u306e\u7d50\u8ad6<\/strong><\/p>\n<\/td>\n

\n

\u30a4\u30f3\u30af\u30ea\u30b7\u30e9\u30f3\u306f\u3001\u5358\u72ec\u3067\u3082\u4ed6\u5264\u3068\u306e\u4f75\u7528\u3067\u3082\u3001\u5e45\u5e83\u3044\u60a3\u8005\u306b\u5c55\u958b\u3057\u3084\u3059\u3044\u8102\u8cea\u4f4e\u4e0b\u7642\u6cd5\u3068\u306a\u308a\u3046\u308b\u3002ORION-4\u8a66\u9a13\u306f\u30a4\u30f3\u30af\u30ea\u30b7\u30e9\u30f3\u306e\u81e8\u5e8a\u7684\u6709\u52b9\u6027\u3092\u8a55\u4fa1\u3059\u308b\u3068\u3068\u3082\u306b\u3001siRNA\u88fd\u5264\u3092\u9577\u671f\u306b\u4f7f\u7528\u3057\u305f\u5834\u5408\u306e\u5b89\u5168\u6027\u306b\u3064\u3044\u3066\u3082\u4fe1\u983c\u3067\u304d\u308b\u30c7\u30fc\u30bf\u3092\u63d0\u4f9b\u3059\u308b\u3053\u3068\u3068\u306a\u3063\u305f\u3002 <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u30b3\u30e1\u30f3\u30c8<\/strong><\/p>\n

PCSK9\u3092\u6a19\u7684\u3068\u3057\u305f\u6cbb\u7642\u85ac\u306e\u4ed6\u306e\u5fc3\u8840\u7ba1\u30a2\u30a6\u30c8\u30ab\u30e0\u8a66\u9a13\uff081,2\uff09\u3068\u540c\u3058\u304f\u3001ORION-4\u8a66\u9a13\u306e\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u30c7\u30fc\u30bf\u304c\u793a\u3059\u306e\u306f\u3001ASCVD\uff08\u4e3b\u306bCHD\uff09\u304c\u78ba\u7acb\u3057\u305f\u9ad8\u9f62\u306e\u60a3\u8005\u96c6\u56e3\u3067\u3042\u308b\u3002\u5927\u534a\u304c\u30b9\u30bf\u30c1\u30f3\u3092\u670d\u7528\u3057\u3066\u3044\u305f\u304c\u3001\u9ad8\u5f37\u5ea6\u30ec\u30b8\u30e1\u30f3\u306f\u7d04\u534a\u6570\u306b\u3068\u3069\u307e\u3063\u305f\u3002\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u304c\u9ad8\u3044\u306b\u3082\u304b\u304b\u308f\u3089\u305a\u300115%\u306f\u30b9\u30bf\u30c1\u30f3\u3092\u670d\u7528\u3057\u3066\u3044\u306a\u304b\u3063\u305f\u3002\u305d\u306e\u4ed6\u306e\u8102\u8cea\u4f4e\u4e0b\u7642\u6cd5\u306e\u4f7f\u7528\u306f\u3054\u304f\u308f\u305a\u304b\u3067\u3042\u3063\u305f\u3002 <\/p>\n

\u4e2d\u7b49\u5ea6\u301c\u9ad8\u5f37\u5ea6\u30b9\u30bf\u30c1\u30f3\u6cbb\u7642\u3092\u80cc\u666f\u306b\u3001\u30a4\u30f3\u30af\u30ea\u30b7\u30e9\u30f3\u304cASCVD\u78ba\u7acb\u60a3\u8005\u306e\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u306e\u6b8b\u4f59\u30ea\u30b9\u30af\u3092\u3055\u3089\u306b\u6e1b\u3089\u305b\u308b\u306e\u304b\u30022027\u5e74\u521d\u982d\u306b\u4e88\u5b9a\u3055\u308c\u308bORION-4\u8a66\u9a13\u306e\u7d50\u679c\u304c\u5f85\u305f\u308c\u308b\u3002<\/p>\n

\u53c2\u8003\u6587\u732e<\/strong><\/p>\n

    \n
  1. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients <\/li>\n<\/ol>\n

    with cardiovascular disease. N Engl J Med 2017; 376: 1713\u201322. <\/p>\n

      \n
    1. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379: 2097\u2013107. <\/li>\n<\/ol>\n

      Key words: ORION-4; inclisiran; siRNA therapeutic; PCSK9-targeted therapy; cardiovascular outcomes study <\/em><\/p>\n<\/div>\n<\/div>\n

      [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

      HPS-4\/TIMI 65\/ORION-4\uff1a\u30a4\u30f3\u30af\u30ea\u30b7\u30e9\u30f3\u306e\u5fc3\u8840\u7ba1\u30a2\u30a6\u30c8\u30ab\u30e0\u8a66\u9a13 2026\u5e7410\u6708 \u30a2\u30c6\u30ed\u30fc\u30e0 […]<\/p>\n","protected":false},"author":258497324,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_wpcom_ai_launchpad_about_page":false,"_wpcom_ai_launchpad_gallery_page":false,"_wpcom_ai_launchpad_contact_page":false,"_wpcom_ai_launchpad_events_page":false,"_wpcom_ai_launchpad_video_page":false,"_wpcom_ai_launchpad_portfolio_piece":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"footnotes":""},"class_list":["post-258195","page","type-page","status-publish","hentry"],"yoast_head":"\nLandmark - October 2026 - R3I<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/r3i.org\/ja\/landmark-october-2026\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Landmark - October 2026 - R3I\" \/>\n<meta property=\"og:description\" content=\"HPS-4\/TIMI 65\/ORION-4\uff1a\u30a4\u30f3\u30af\u30ea\u30b7\u30e9\u30f3\u306e\u5fc3\u8840\u7ba1\u30a2\u30a6\u30c8\u30ab\u30e0\u8a66\u9a13 2026\u5e7410\u6708 \u30a2\u30c6\u30ed\u30fc\u30e0 […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/r3i.org\/ja\/landmark-october-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"R3I\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-09T15:42:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data1\" content=\"2\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/landmark-october-2026\\\/\",\"url\":\"https:\\\/\\\/r3i.org\\\/ja\\\/landmark-october-2026\\\/\",\"name\":\"Landmark - October 2026 - R3I\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/#website\"},\"datePublished\":\"2026-10-09T15:41:55+00:00\",\"dateModified\":\"2026-10-09T15:42:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/landmark-october-2026\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/r3i.org\\\/ja\\\/landmark-october-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/landmark-october-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/r3i.org\\\/ja\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Landmark – October 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/#website\",\"url\":\"https:\\\/\\\/r3i.org\\\/ja\\\/\",\"name\":\"R3I\",\"description\":\"Residual Risk Reduction Initiative\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/r3i.org\\\/ja\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Landmark - October 2026 - R3I","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/r3i.org\/ja\/landmark-october-2026\/","og_locale":"ja_JP","og_type":"article","og_title":"Landmark - October 2026 - R3I","og_description":"HPS-4\/TIMI 65\/ORION-4\uff1a\u30a4\u30f3\u30af\u30ea\u30b7\u30e9\u30f3\u306e\u5fc3\u8840\u7ba1\u30a2\u30a6\u30c8\u30ab\u30e0\u8a66\u9a13 2026\u5e7410\u6708 \u30a2\u30c6\u30ed\u30fc\u30e0 […]","og_url":"https:\/\/r3i.org\/ja\/landmark-october-2026\/","og_site_name":"R3I","article_modified_time":"2026-10-09T15:42:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/r3i.org\/ja\/landmark-october-2026\/","url":"https:\/\/r3i.org\/ja\/landmark-october-2026\/","name":"Landmark - October 2026 - R3I","isPartOf":{"@id":"https:\/\/r3i.org\/ja\/#website"},"datePublished":"2026-10-09T15:41:55+00:00","dateModified":"2026-10-09T15:42:00+00:00","breadcrumb":{"@id":"https:\/\/r3i.org\/ja\/landmark-october-2026\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/r3i.org\/ja\/landmark-october-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/r3i.org\/ja\/landmark-october-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/r3i.org\/ja\/"},{"@type":"ListItem","position":2,"name":"Landmark – October 2026"}]},{"@type":"WebSite","@id":"https:\/\/r3i.org\/ja\/#website","url":"https:\/\/r3i.org\/ja\/","name":"R3I","description":"Residual Risk Reduction Initiative","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/r3i.org\/ja\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"}]}},"jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/Pgbfv2-15ar","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/258195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/users\/258497324"}],"replies":[{"embeddable":true,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/comments?post=258195"}],"version-history":[{"count":2,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/258195\/revisions"}],"predecessor-version":[{"id":258197,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/258195\/revisions\/258197"}],"wp:attachment":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/media?parent=258195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}